[Experimental models of Parkinson's disease].
Parkinson's disease is a neurodegenerative condition who is related to a large loss of nigral dopaminergic neurons leading to a depletion of dopamine in the striatum. Experimental research is required in order to increase our knowledge on the cellular mechanism and functional consequences of this degenerative process. These models allow investigations of new therapeutics in order to improve the treatment of patients or to test new drugs able to protect any remaining dopaminergic neurons. It is relatively easy to obtain animal models of this disease since the target structure and the neuronal population are clearly defined. Two neurotoxic compounds are available for inducing animal models of Parkinson's disease, 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). A new one, rotenone, requires further investigations. Each of the neurotoxic compounds requires a specific protocol which can be used either with rodents or non-human primates. Progressive lesioning, using MPTP on green african monkeys (Cercopithecus aethiops sabaeus) provides the most reliable model of the idiopathic disease.
Féger
J
J
Inserm U 289  Neurologie et Thérapeutique Expérimentale , Hôpital de La Salpêtrière, 47 boulevard de l'Hôpital F 75013 Paris.
Pessigliore
M
M
François
C
C
Tremblay
L
L
Hirsch
E
E
D000818:Animals; D004195:Disease Models, Animal; D000882:Haplorhini; D009498:Neurotoxins; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology*; D051381:Rats
D009498:Neurotoxins